Industry news

Colin Kerr

Posted: Saturday, May 1, 2021

FDA Clearance
The new OCULUS Pentacam® AXL Wave has received the 510(k) clearance of the US Food and Drug Administration (FDA). “The Pentacam® AXL Wave represents the continued development of the successful and time-proven Pentacam® portfolio,” said an Oculus spokeswoman. “The established functions of anterior segment tomography and optical biometry have been complemented by retroillumination and a Hartman-Shack sensor for total eye wavefront and objective refraction,” she said.
Oculus say the Pentacam® AXL Wave incorporates intuitive reports based on clinical studies, with guaranteed network compatibility and full operability of all Pentacam® software and examinations. A new examination routine guides the user through the imaging process. The measuring process is straightforward, user-independent, fast and patient-friendly. The intuitive guide allows both eyes to be examined in less than five minutes.
NIDEK has launched the RT-6100 CB for Windows, an optional control software for the RT-6100 Intelligent Refractor and the TS-610 Tabletop Refraction System. “This software adapts to the varying needs of patients and operators.
Additionally, the software allows refractions that meet social distancing needs. RT-6100 CB for Windows simultaneously offers convenience and safety.” said Motoki Ozawa, President and CEO of NIDEK CO., LTD. “We are committed to providing comprehensive refraction systems that maintain patient and operator comfort while adapting to changing clinical requirements,” he said.
Santen has launched PURALID LIPOGEL, an ophthalmic gel for blepharitis that soothes and cleanses the eyelids and periocular area.
“Blepharitis is a common and symptomatic disease and it has no established cure. It’s therefore crucial that we recognise that this condition needs a careful diagnostic approach and personalised management, and that we continue to educate patients on the value of lid hygiene, such as using warm compresses and cleansing the eyelids daily,” said Professor Edoardo Villani, University of Milan, Italy.

Latest Articles

escrs members advert